70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast CancerFátima Cardoso, Martine Piccart, Laura J. van’t Veer et al.|New England Journal of Medicine|2016Cited by 2k
HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Erika Hamilton et al.|Journal of Clinical Oncology|2020Cited by 801
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized studyLuca Gianni, Giuseppe Viale|Annals of Oncology|2022Cited by 382
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by ageMartine Piccart, Emiel J. Rutgers, Laura van ‘t Veer et al.|The Lancet Oncology|2021Cited by 355
Assessment of a HER2 scoring system for colorectal cancer: results from a validation studyEmanuele Valtorta, Marcello Gambacorta, Barbara Frau et al.|Modern Pathology|2015Cited by 317